Data protection Impressum

Pharma

Established in the canton of Valais since 1989, Debiopharm is building a full-scale research and innovation campus in Martigny.

Debiopharm invests CHF 30 million in Valais amidst workforce surge

26 October 2023

On 19 September 2023, Mecaplast Swiss, a 50-year veteran in plastic injection with a medtech specialization, welcomed 50 Swiss Health Valley members on the occasion of BioAlps’ 4à6 event.

Mecaplast Swiss, 50 years of innovation in the canton of Fribourg

24 October 2023

Valsynthèse’s name originates from the high-energy value of the chemical reactions involved, necessitating a special skill set for manipulation.

Valsynthèse, 40 years of innovation in the canton of Valais

23 October 2023

The latest collaboration complements Vaxcyte’s strategy to commence the initial commercial launch of VAX-24, a vaccine that targets the prevention of invasive pneumococcal disease (IPD).

Lonza expands to manufacture Vaxcyte’s pneumococcal conjugate vaccine

17 October 2023

CDMOs play a crucial role in the pharmaceutical sector, serving as key partners in the drug development and production process.

Siegfried and Lonza secure top positions in global pharmaceutical outsourcing rankings

16 October 2023

PULSE, with its distinctive amalgamation of adaptable, future-proof infrastructure, is set to become a pivotal hub designed to uplift and expand the frontiers of biotech and various scientific ventures.

PULSE, a modular innovation center in the heart of the Health Valley

10 October 2023

Lonza continues to fortify its position in ADC production, expanding collaboration and infrastructure to enhance its acclaimed Ibex Dedicate Biopark.

Lonza further extends its ADC manufacturing capabilities in Visp

9 October 2023

The Institute of Life Technologies of the HES-SO Valais/Wallis has forged a five-year collaboration with Debiopharm Research & Manufacturing to develop new targeted antibody fragment vectorization technologies.

HES-SO Valais-Wallis and Debiopharm partner up to battle cancer

4 October 2023

Nagi Bioscience is at the cusp of redefining the landscape of next-generation drug discovery and chemical testing technologies, placing humane testing solutions within arm’s reach of the global scientific community.

Nagi Bioscience secures CHF 12.4 million to propel animal-alternative testing

3 October 2023

Backed by its parent company Nanobacterie's fourth-place in nanomedicine patent rankings by Marks and Clerk, AlphaOnco Swiss channels the synergy of Franco-Swiss collaboration to bring forth groundbreaking cancer treatments.

Nanomedicine pioneer Nanobacterie achieves remarkable patent ranking

23 August 2023

1 … 4 5 6 7 8 9 10 11 12 … 15